



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



Atuliflapon

Cat. No.:	HY-122908		
CAS No.:	2041075-86-7		
Molecular Formula:	C ₂₄ H ₂₆ N ₆ O ₃		
Molecular Weight:	446.5		
Target:	FLAP		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (279.96 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.2396 mL	11.1982 mL	22.3964 mL
		5 mM		0.4479 mL	2.2396 mL	4.4793 mL
		10 mM		0.2240 mL	1.1198 mL	2.2396 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.66 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.66 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.66 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Atuliflapon (AZD5718) is an orally active inhibitor of FLAP (5-Lipoxygenase activating protein), with an IC ₅₀ of 2 nM. Atuliflapon is used in the study for coronary artery disease ^[1] .
IC ₅₀ & Target	IC ₅₀ : 2 nM (FLAP) ^[1] .
In Vitro	Atuliflapon demonstrates a dose dependent and greater than 90% suppression of leukotriene production over 24 h ^[1] . Atuliflapon exhibits an IC ₅₀ of 39 nM for LTB ₄ ^[1] .

	MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Atuliflapon exhibits t _{1/2} of 0.45 h and 2.1 h in rat and dog by iv injection, respectively ^[1] . Atuliflapon shows no inhibition of 5-LO pathway activity in rodent blood ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Daniel Pettersen, et al. Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease. J Med Chem. 2019 May 9;62(9):4312-4324.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA